Browse Category

NYSE:BKD News 16 January 2026 - 29 January 2026

Brookdale Senior Living stock jumps on early 2025 results and fresh 2026 outlook ahead of Investor Day

Brookdale Senior Living stock jumps on early 2025 results and fresh 2026 outlook ahead of Investor Day

Brookdale Senior Living shares surged nearly 11% Thursday after releasing preliminary 2025 results and its first full-year 2026 forecast. The company projects 2026 adjusted EBITDA of $502 million to $516 million and expects RevPAR growth of 8% to 9%. Brookdale reported a 2025 net loss of about $263 million, including $71 million in non-cash impairment charges. Wall Street analysts raised price targets ahead of Investor Day.

Stock Market Today

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

7 February 2026
New York, Feb 7, 2026, 15:18 EST — Market closed. Philip Morris International shares last stood at $182.81, up 0.45% from the prior session, after the company laid out a higher 2026 profit outlook tied to its nicotine pouch business. (Reuters) That matters now because the stock has become a referendum on whether smoke-free products can keep carrying earnings while the category gets crowded. Zyn is the big swing factor, and traders are watching for any sign that volume gains are coming at the cost of pricing power. With U.S. markets shut for the weekend, the next test comes at
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop